NYSE Shariah screener · October 2026

Is Charles River Laboratories International, Inc. (CRL) Halal?

PASS

Charles River Laboratories International, Inc. · NYSE: CRL · Healthcare

The short answer

Charles River Laboratories passes all three Shariah gates: it is a contract research organization serving drug discovery and development (no haram business lines), carries $2.14 billion of long-term debt (15.4% of its ~$13.88 billion market cap), and interest income of 0.12% of revenue is far under the 5% ceiling. Zoya and Musaffa both rate it compliant.

Gate 1 — Business activity: PASS

Gate 1 — business activity: PASS. Charles River Laboratories International, Inc., headquartered in Wilmington, Massachusetts, is a contract research organization (CRO) supporting pharmaceutical and biotechnology companies across drug discovery and development. Per its FY2025 Form 10-K, it operates three segments: Research Models and Services (laboratory research models and related support), Discovery and Safety Assessment (nonclinical studies), and Manufacturing Solutions (testing and support for biological drug production). FY2025 total revenue was $4,015,382 thousand (service revenue $3,250,099 thousand plus product revenue $765,283 thousand).

The company provides preclinical research services — not interest-based lending, and not involved in tobacco, gambling, pork or alcohol. Its business passes gate 1.

Gate 2 — Debt and cash: PASS

Gate 2 — interest-bearing debt: PASS (15.4%, ceiling 33%). Per the FY2025 Form 10-K consolidated balance sheet, ‘Long-term debt, net and finance leases’ were $2,136,360 thousand at December 27, 2025. Operating lease right-of-use liabilities ($434,048 thousand) are excluded — they are not interest-bearing debt.

$2.14 billion of interest-bearing debt against a market capitalization of about $13.88 billion (Finnhub, October 2, 2026) is 15.4%, well under the 33% ceiling. Cash and cash equivalents of $213,770 thousand at December 27, 2025 represent about 1.5% of market cap.

Gate 3 — Non-compliant income: PASS

Gate 3 — non-compliant income: PASS (0.12%, ceiling 5%). The FY2025 Form 10-K consolidated statements of income separately disclose ‘Interest income’ of $4,940 thousand against total revenue of $4,015,382 thousand — about 0.12%, far under the 5% ceiling. (Interest expense was $107,029 thousand — reported here for completeness, not counted in the gate.)

Key figures used

Business: contract research organization, HQ Wilmington, MA; three segments: Research Models and Services, Discovery and Safety Assessment, Manufacturing Solutions; FY2025 revenue $4,015,382K (services $3,250,099K + products $765,283K); clients in North America, Europe, Asia Pacific
Haram assessment: preclinical research services — no interest-based lending; no tobacco/gambling/pork/alcohol
Debt: $2,136,360K long-term debt net and finance leases at Dec 27, 2025; operating leases excluded; 15.4% of ~$13.88B market cap (Finnhub, Oct 2, 2026) — well under the 33% ceiling
Cash: $213,770K cash and cash equivalents at Dec 27, 2025 (~1.5% of market cap)
Interest income: $4,940K in FY2025 vs $4,015,382K revenue = 0.12% — far under the 5% ceiling (interest expense $107,029K reported separately)
Market data: NYSE-listed (confirmed on the 10-K cover and Finnhub XNYS); still listed (confirmed October 2, 2026; live quotes, no delisting); FY2025 10-K filed February 18, 2026; 2026 corporate actions noted: Elliott settlement (four new directors, strategic review) and European site/asset sales
Third-party: Zoya flags CRL Shariah-compliant; Musaffa classifies CRL halal (Oct 2026); no verifiable ShariaPortfolio rating found

Frequently asked questions

What does Charles River Laboratories do?

Charles River Laboratories International, Inc. (NYSE: CRL), headquartered in Wilmington, Massachusetts, is a contract research organization (CRO) that supports pharmaceutical and biotechnology companies across the drug development process, from early discovery through preclinical safety testing. Per its FY2025 Form 10-K, it operates three segments: Research Models and Services (laboratory research models and related support), Discovery and Safety Assessment (nonclinical studies), and Manufacturing Solutions (testing and support for biological drug production). It serves clients across North America, Europe, and the Asia Pacific region.

Is Charles River Laboratories' business Shariah compliant?

Yes. Charles River provides preclinical research services — research models, nonclinical drug-safety studies, and manufacturing support for biological drugs — not interest-based lending, and it is not involved in tobacco, gambling, pork or alcohol. Its business passes this screener's first gate.

How much interest-bearing debt does Charles River Laboratories have?

Per its FY2025 Form 10-K, Charles River had 'Long-term debt, net and finance leases' of $2,136,360 thousand at December 27, 2025. Operating lease right-of-use liabilities of $434,048 thousand are excluded as they are not interest-bearing debt. $2.14 billion against a market cap of about $13.88 billion (Finnhub, October 2, 2026) is 15.4%, well under the 33% ceiling. Cash and cash equivalents of $213,770 thousand are about 1.5% of market cap.

How much interest income does Charles River Laboratories earn?

Charles River's FY2025 Form 10-K separately discloses 'Interest income' of $4,940 thousand. Against FY2025 total revenue of $4,015,382 thousand that is about 0.12%, far under the 5% non-compliant income ceiling.

What do third-party Shariah screeners say about Charles River Laboratories?

Zoya publishes a Charles River Laboratories (CRL) page and currently flags the stock as Shariah-compliant. Musaffa also classifies CRL as halal as of October 2026. No ShariaPortfolio rating could be verified from public sources. Third-party screeners apply different assumptions and update on different schedules, and their results can change when new financial statements are published — always check the latest screenings before investing.

Sources

Screened 2026-10-02 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.

Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).